Skip to main content
Terug
Watch Compare

MEDICINOVA INC

Datakwaliteit: 100%
MNOV
NASDAQ Manufacturing Chemicals
€ 1,45
▲ € 0,01 (0,69%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-43,56%

Groei

Revenue Growth (5Y)
-43,56%
Onder sectorgemiddelde (1,72%)
Revenue (1Y)-59,03%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-26,42%
Boven sectorgemiddelde (-54,68%)
ROIC-22,96%
Net Margin-2928,78%
Op. Margin-3242,47%

Veiligheid

Debt / Equity
N/A
Current Ratio9,86
Interest CoverageN/A

Waardering

P/E Ratio
-5,95 TTM
-3,45 NTM
Onder sectorgemiddelde (-1,49)
P/B Ratio1,62
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -43,56% annually over 5 years
Negative free cash flow of -9,81 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 15,47%
Capital efficient — spends only 0,71% of revenue on capex

Price History

Financiële Trends

Koersdoel Analisten

4 analisten
Buy
+520.7%
upside to target
Huidig
€ 1,45
Consensus Target
€ 9,00
€ 6,00
Laag
€ 11,00
Hoog
Vooruitzicht
Forward K/W
-3,45
Forward WPA
-€ 0,42
Omzet Sch.
233.330,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,06 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,06 -€ 0,07 -€ 0,06 -€ 0,05 — —
Estimate -€ 0,14 -€ 0,12 -€ 0,12 -€ 0,10 -€ 0,06 -€ 0,06
Verrassing +57,14% +41,67% +50,00% +47,37% — —

Growth

Rev 5Y: -43,56% · Earnings 1Y: N/A
Revenue Growth (1Y) -59,03% Revenue Growth (3Y) -36,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -43,56% Earnings Growth (5Y) N/A

Profitability

ROE: -26,42% · Net Margin: -2928,78%
Revenue (TTM) 409.657,0 Net Income (TTM) -12,00 M
ROE -26,42% ROA -24,64%
Gross Margin N/A Operating Margin -3242,47%
Net Margin -2928,78% Free Cash Flow (TTM) -9,81 M
ROIC -22,96% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 9,86
Debt / Equity N/A Current Ratio 9,86
Interest Coverage N/A Asset Turnover 0,01
Working Capital 29,59 M Tangible Book Value 34,36 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -5,95 · EV/EBITDA: N/A
P/E Ratio -5,95 Forward P/E -3,45
P/B Ratio 1,62 P/S Ratio 174,22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 305,88 Fwd Earnings Yield N/A
FCF Yield -13,75%
Market Cap 71,37 M Enterprise Value 38,81 M

Per Share

EPS: -0,24 · FCF/Share: -0,20
EPS (Diluted TTM) -0,24 Revenue / Share 0,01
FCF / Share -0,20 OCF / Share -0,20
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 81,79% · CapEx/Rev: 0,71%
CapEx / Revenue 0,71% FCF Conversion 81,79%
SBC-Adj. FCF -10,68 M Growth Momentum -15,47

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 409.657,0 1,00 M 1,00 M 4,04 M 4,04 M
Net Income -12,00 M -11,05 M -8,57 M -14,07 M -10,13 M
EPS (Diluted) -0,24 -0,23 -0,17 -0,29 —
Gross Profit — — — — —
Operating Income -13,28 M -12,68 M -9,90 M -14,63 M -10,22 M
EBITDA — — — — —
R&D Expenses 6,70 M 6,80 M 5,30 M 8,70 M 8,10 M
SG&A Expenses — — — — —
D&A 20.099,0 21.077,0 20.295,0 17.707,0 26.149,0
Interest Expense — — — — —
Income Tax 5.994,0 5.537,0 3.047,0 2.822,0 2.568,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 45,60 M 55,88 M 66,27 M 74,15 M 87,41 M
Total Liabilities 4,02 M 3,37 M 3,89 M 3,91 M 3,73 M
Shareholders' Equity 41,59 M 52,50 M 62,38 M 70,24 M 83,68 M
Total Debt — — — — —
Cash & Equivalents 30,81 M 40,36 M 51,00 M 18,51 M 71,43 M
Current Assets 30,99 M 41,07 M 51,17 M 58,99 M 72,01 M
Current Liabilities 3,80 M 2,96 M 3,28 M 3,19 M 2,83 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -6,0 -1,5
P/B 1,6 1,6
ROE % -26,4 -54,7
Net Margin % -2928,8 -41,5
Rev Growth 5Y % -43,6 1,7
D/E — 0,3

ETFs Holding This Stock
BRSIX BRSIX
0,14% weight